Journal of Community Health
Volume 47, issue 2, April 2022
https://link.springer.com/journal/10900/volumes-and-issues/47-2
COVID-19 Vaccine Uptake Among College Students at a Midwest University
Authors (first, second and last of 8)
Amy J. Wotring
Matthew Hutchins
Linda Behrendt
Content type: Original Paper
Published: 20 November 2021
Pages: 292 – 297
Journal of Travel Medicine
Volume 29, Issue 2, March 2022
https://academic.oup.com/jtm/issue
Original Articles
Using social media listening and data mining to understand travellers’ perspectives on travel disease risks and vaccine-related attitudes and behaviours
Catherine Bravo, PhD, Valérie Bosch Castells, MSc, Susann Zietek-Gutsch, MBA, Pierre-Antoine Bodin, MSc, Cliona Molony, PhD …
The Lancet
Mar 26, 2022 Volume 399 Number 10331 p1201-1278, e17-e19
https://www.thelancet.com/journals/lancet/issue/current
Comment
Evaluating COVID-19 vaccines in the real world
Edward J Mills, Gilmar Reis
The Lancet
Mar 26, 2022 Volume 399 Number 10331 p1201-1278, e17-e19
https://www.thelancet.com/journals/lancet/issue/current
Articles
Effectiveness and cost-effectiveness against malaria of three types of dual-active-ingredient long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs in Tanzania: a four-arm, cluster-randomised trial
Jacklin F Mosha, et al.
The Lancet
Mar 26, 2022 Volume 399 Number 10331 p1201-1278, e17-e19
https://www.thelancet.com/journals/lancet/issue/current
The Lancet
Mar 26, 2022 Volume 399 Number 10331 p1201-1278, e17-e19
https://www.thelancet.com/journals/lancet/issue/current
Health Policy
NCD Countdown 2030: efficient pathways and strategic investments to accelerate progress towards the Sustainable Development Goal target 3.4 in low-income and middle-income countries
NCD Countdown 2030 collaborators
Maternal and Child Health Journal
Volume 26, issue 3, March 2022
https://link.springer.com/journal/10995/volumes-and-issues/26-3
Original Paper
Knowledge, Attitude, and Practice of Cervical Cancer Screening, and HPV Vaccination: A Cross-Sectional Study Among Obstetricians and Gynecologists in Egypt
Authors (first, second and last of 4)
Mariam Lotfy Mohamed, Ayat Mahmoud Tawfik, Sally Fawzy Elotla
Published: 21 January 2022
Pages: 565 – 574
Nature
Volume 603 Issue 7902, 24 March 2022
https://www.nature.com/nature/volumes/603/issues/7901
Editorial | 21 March 2022
The alarming rise of complex genetic testing in human embryo selection
Companies are marketing polygenic risk scores as part of IVF well ahead of a full understanding of the potential benefits — or dangers.
Nature
Volume 603 Issue 7902, 24 March 2022
https://www.nature.com/nature/volumes/603/issues/7901
Editorial | 23 March 2022
This is no time to stop tracking COVID-19
To live with the coronavirus, we cannot be blind to its movements.
Nature
Volume 603 Issue 7902, 24 March 2022
https://www.nature.com/nature/volumes/603/issues/7901
Correspondence | 22 March 2022
Vaccinating women against COVID in world’s largest refugee camp
Ali Alam
Last year’s vaccination campaign in the refugee camp in Cox’s Bazar, Bangladesh, which houses some 900,000 Rohingya refugees who fled genocide in Myanmar in 2017, led to more than half of the eligible population being fully vaccinated in 4 months (see go.nature.com/3q7ukca). Vaccine uptake was notably successful among women.
Among marginalized people, the vaccination rate for women is usually lower than for their male counterparts (see, for example, go.nature.com/3i6wask). This is down to gender-specific misinformation and gender gaps in accessing information and vaccination centres, for example. Nevertheless, more than 80% of women in the target group for COVID-19 vaccines were vaccinated in the first month of the Cox’s Bazar programme (see go.nature.com/3kfopy2).
Engagement with community leaders over gender-based barriers to vaccination led to education programmes designed to combat false rumours. This in turn led to the recruitment of female vaccinators, and to vaccine misinformation being discussed at women-only radio listeners’ clubs and religious group-study sessions.
As a health-care researcher who has worked with Rohingya refugees, I think this reflects the importance of including women themselves in such campaigns.
Nature
Volume 603 Issue 7902, 24 March 2022
https://www.nature.com/nature/volumes/603/issues/7901
Review Article | 28 January 2022
Human genetic and immunological determinants of critical COVID-19 pneumonia
The COVID Human Genetic Effort examines the molecular, cellular and immunological determinants of the various SARS-CoV-2-related disease manifestations by searching for causal errors of immunity.
Qian Zhang, Paul Bastard, Jean-Laurent Casanova
Nature
Volume 603 Issue 7902, 24 March 2022
https://www.nature.com/nature/volumes/603/issues/7901
Article | 07 January 2022 | Open Access
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
The genomic profile and early transmission dynamics of the Omicron strain of SARS-CoV-2.
Raquel Viana, Sikhulile Moyo, Tulio de Oliveira
Nature Human Behaviour
Volume 6 Issue 3, March 2022
https://www.nature.com/nathumbehav/volumes/6/issues/3
World View | 07 February 2022
Understanding the nature of science through COVID-19 reports
Teaching students the nature of science can be difficult, but the COVID-19 pandemic offers a range of teachable examples in a form of ‘living textbook’, explains Wei-Zhao Shi.
Wei-Zhao Shi
Nature Medicine
Volume 28 Issue 3, March 2022
https://www.nature.com/nm/volumes/28/issues/3
Perspective | 10 March 2022
An epidemic of uncertainty: rumors, conspiracy theories and vaccine hesitancy
In this Perspective, the authors discuss the new digital communications landscape in relation to vaccines and argue that trust is key to overcoming vaccine hesitancy.
Ed Pertwee, Clarissa Simas, Heidi J. Larson
Nature Medicine
Volume 28 Issue 3, March 2022
https://www.nature.com/nm/volumes/28/issues/3
Review Article | 10 March 2022
Misinformation: susceptibility, spread, and interventions to immunize the public
This Review provides an overview of the psychology of misinformation, from susceptibility to spread and interventions to help boost psychological immunity.
Sander van der Linden
Nature Medicine
Volume 28 Issue 3, March 2022
https://www.nature.com/nm/volumes/28/issues/3
Article | 13 January 2022 | Open Access
SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland
Findings from the COVID-19 in Pregnancy in Scotland (COPS) study reveals low levels of vaccination uptake by pregnant women compared to women in the general population and that not being vaccinated is associated with increased risk of severe complications of COVID-19 in pregnancy, including perinatal mortality.
Sarah J. Stock, Jade Carruthers, Rachael Wood
New England Journal of Medicine
March 24, 2022 Vol. 386 No. 12
https://www.nejm.org/toc/nejm/medical-journal
Editorial
Addressing Vaccine Inequity — Covid-19 Vaccines as a Global Public Good
List of authors.
David J. Hunter, F.Med.Sci., Salim S. Abdool Karim, M.B., Ch.B., Ph.D., Lindsey R. Baden, M.D., Jeremy J. Farrar, M.D., Ph.D., Mary Beth Hamel, M.D., M.P.H., Dan L. Longo, M.D., Stephen Morrissey, Ph.D., and Eric J. Rubin, M.D., Ph.D.
[See Featured Journal Content above for full text]
PLoS One
http://www.plosone.org/
[Accessed 26 Mar 2022]
Research Article
Perceived risk and perceptions of COVID-19 vaccine: A survey among general public in Pakistan
Bilal Mahmood Beg, Tariq Hussain, Mehmood Ahmad, Sadaf Areej, Arfa Majeed, Muhammad Adil Rasheed, Muhammad Moin Ahmad, Qurat-ul-Ain Shoaib, Sadaf Aroosa
Research Article | published 24 Mar 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0266028
PLoS One
http://www.plosone.org/
[Accessed 26 Mar 2022]
Ethical, regulatory, and practical barriers to COVID-19 research: A stakeholder-informed inventory of concerns
Bryan A. Sisk, Kari Baldwin, Meredith Parsons, James M. DuBois
Research Article | published 24 Mar 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0265252
PLoS One
http://www.plosone.org/
[Accessed 26 Mar 2022]
Potential factors influencing COVID-19 vaccine acceptance and hesitancy: A systematic review
Debendra Nath Roy, Mohitosh Biswas, Ekramul Islam, Md. Shah Azam
Research Article | published 23 Mar 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0265496
PLoS One
http://www.plosone.org/
[Accessed 26 Mar 2022]
Knowledge attitudes and practices toward seasonal influenza vaccine among pregnant women during the 2018/2019 influenza season in Tunisia
Sonia Dhaouadi, Ghassen Kharroubi, Amal Cherif, Ines Cherif, Hind Bouguerra, Leila Bouabid, Nourhene Najar, Adel Gharbi, Afif Ben Salah, Nissaf Bouafif ép Ben Alaya, Jihene Bettaieb
Research Article | published 22 Mar 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0265390
PNAS – Proceedings of the National Academy of Sciences of the United States
March 8, 2022 | vol. 119 | no. 10
https://www.pnas.org/toc/pnas/119/10
Perspective February 24, 2022 Open Access
Inequality in science and the case for a new agenda
The history of the scientific enterprise demonstrates that it has supported gender, identity, and racial inequity. Further, its institutions have allowed discrimination, harassment, and personal harm of racialized persons and women. This has resulted in a …
Joseph L. Graves, Maureen Kearney, […] Shirley Malcom
Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 26 Mar 2022]
Acceptance of COVID-19 vaccination during pregnancy among Thai pregnant women and their spouses: a prospective survey
Vaccination is one of the most reliable interventions against coronavirus disease 2019 (COVID-19). Although pregnant women’s attitudes toward COVID-19 vaccination are well studied, husbands’ views toward COVID…
Authors: Kotchakorn Pairat and Chadakarn Phaloprakarn
Citation: Reproductive Health 2022 19:74
Content type: Research Published on: 24 March 2022
Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
23 Mar 2022
Primary health care expenditure in the Americas: measuring what matters
Special report | Spanish |
Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
23 Mar 2022
Combination of COVID-19 vaccines and their efficacy: a theoretical proposal
Brief communication | Spanish |
Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
23 Mar 2022
Hepatitis B in indigenous people in Latin America: a literature review
Review | Spanish |
Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
23 Mar 2022
Estimating national excess mortality from subnational data: application to Argentina
Brief communication | English |
Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
23 Mar 2022
Feasibility of using artificial intelligence for screening COVID-19 patients in Paraguay
Original research | Spanish |
Science
Volume 375| Issue 6587| 25 Mar 2022
https://www.science.org/toc/science/current
Policy Forum
Will the European Health Data Space change data sharing rules?
BY Mahsa Shabani
24 Mar 2022: 1357-1359
Questions of consent and public interest research loom large
Science Translational Medicine
Volume 14| Issue 637| 23 Mar 2022
https://www.science.org/toc/stm/current
Research Articles
Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection
BY John P. Evans, et al.
23 Mar 2022
Open Access
SARS-CoV-2–specific neutralizing antibodies induced by two doses of mRNA vaccine wane after 6 months but increase after breakthrough infection.
Social Science & Medicine
Volume 294 February 2022
https://www.sciencedirect.com/journal/social-science-and-medicine/vol/294/suppl/C
Research article Full text access
Multi-dimensional factors related to participation in a population-wide mass COVID-19 testing program among Hong Kong adults: A population-based randomized survey
Meiqi Xin, Joseph Tak-fai Lau, Mason M.C. Lau
Article 114692
Social Science & Medicine
Volume 294 February 2022
https://www.sciencedirect.com/journal/social-science-and-medicine/vol/294/suppl/C
Research article Full text access
Bodies-in-waiting as infrastructure: Assembling the Philippine Government’s disciplinary quarantine response to COVID-19
Nico A. Canoy, Augil Marie Q. Robles, Gilana Kim T. Roxas
Article 114695
Vaccine
Volume 40, Issue 10 Pages 1385-1512 (1 March 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/10
Research article Open access
Italy’s rollout of COVID-19 vaccinations: The crucial contribution of the first experimental mass vaccination site in Lombardy
Francesco Oliani, Antonella Savoia, Giulia Gallo, Navpreet Tiwana, … Silvana Castaldi
Pages 1397-1403
Vaccine
Volume 40, Issue 10 Pages 1385-1512 (1 March 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/10
Research article Full text access
Looking ahead: Caregivers’ COVID-19 vaccination intention for children 5 years old and younger using the health belief model
Morgan E. Ellithorpe, Fashina Aladé, Robyn B. Adams, Glen J. Nowak
Pages 1404-1412
Pre-Print Servers
Gates Open Research
https://gatesopenresearch.org/browse/articles
Open Letter metrics AWAITING PEER REVIEW
Implementing adaptive youth-centered adolescent sexual reproductive health programming: learning from the Adolescents 360 project in Tanzania, Ethiopia, and Nigeria (2016-2020) [version 1; peer review: awaiting peer review]
Matthew Wilson, Meghan Cutherell, Abednego Musau, Sara Malakoff, Alexis Coppola, Metsehate Ayenekulu, Edwin Mtei, Fifi Ogbondeminu
Peer Reviewers Invited
Funders
Bill and Melinda Gates Foundation
Children’s Investment Fund Foundation
PUBLISHED 25 Mar 2022
medRxiv
https://www.medrxiv.org/content/about-medrxiv
medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints – complete but unpublished manuscripts – that describe human health research conducted, analyzed, and interpreted according to scientific principles…
A Qualitative Study Regarding Messages of the COVID-19 Vaccine from Vaccinated Healthcare Providers and Healthy Adults
Shuji Sano, Satomi Sato, Norio Ohmagari, Osamu Takahashi
medRxiv 2022.03.24.22272878; doi: https://doi.org/10.1101/2022.03.24.22272878
International comparison of the impact of the pandemic and vaccination measures adopted on children and adolescent population
Luis Rajmil, Maria Camila Pinzon-Segura, Seth Christopher Yaw Appiah, Bernadine Ekpenyong, Fernando Gonzalez, Zuhal Gundogdu, Selim Oncel, Ozlem Cakici
medRxiv 2022.03.24.22272863; doi: https://doi.org/10.1101/2022.03.24.22272863
Booster dose of BNT162b2 in a CoronaVac primary vaccination protocol improves neutralization of SARS-CoV-2 Omicron variant
Guilherme R. F. Campos, Nathalie B. F. Almeida, Priscilla S. Filgueiras, Camila A. Corsini, Sarah V. C. Gomes, Daniel A. P. de Miranda, Jessica V. de Assis, Thais Barbara S. Silva, Pedro A Alves, Gabriel R. Fernandes, Jaquelline G. de Oliveira, Paula Rahal, Rafaella F. Q. Grenfell, Mauricio L Nogueira
medRxiv 2022.03.24.22272904; doi: https://doi.org/10.1101/2022.03.24.22272904
Impact assessment of mobility restriction, testing, and vaccination on the COVID-19 pandemic in India
Jeonghyun Shin, Quynh Long Khuong, Kaja Abbas, Juhwan Oh
medRxiv 2022.03.24.22272864; doi: https://doi.org/10.1101/2022.03.24.22272864
Vaccine Effectiveness Against Hospitalization Among Adolescent and Pediatric SARS-CoV-2 Cases in Ontario, Canada
Alison E. Simmons, Afia Amoako, Alicia Grima, Kiera Murison, Ashleigh Tuite, David Fisman
medRxiv 2022.03.24.22272919; doi: https://doi.org/10.1101/2022.03.24.22272919
Vaccine Adverse Event Reporting System (VAERS): Evaluation of 31 Years of Reports and Pandemics’ Impact
Ohoud Almadani, Thamir M Alshammari
medRxiv 2022.03.23.22272819; doi: https://doi.org/10.1101/2022.03.23.22272819
Systematic review and meta-analysis of yellow fever vaccine in elderly population
Ariane de Jesus Lopes de Abreu, João Roberto Cavalcante, Letícia Wigg de Araújo Lagos, Rosângela Caetano, José Ueleres Braga
medRxiv 2022.03.23.22272849; doi: https://doi.org/10.1101/2022.03.23.22272849
Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong
Martina E. McMenamin, Joshua Nealon, Yun Lin, Jessica Y. Wong, Justin K. Cheung, Eric H. Y. Lau, Peng Wu, Gabriel M. Leung, Benjamin J. Cowling
medRxiv 2022.03.22.22272769; doi: https://doi.org/10.1101/2022.03.22.2227276
Vaccine Equity in Low and Middle Income Countries: A Systematic Review and Meta-analysis
Huda Ali, Anna-Maria Hartner, Susy Echeverria-Londono, Jeremy Roth, Xiang Li, Kaja Abbas, Allison Portnoy, Emilia Vynnycky, Kim Woodruff, Neil M Ferguson, Jaspreet Toor, Katy AM Gaythorpe
medRxiv 2022.03.23.22272812; doi: https://doi.org/10.1101/2022.03.23.22272812
The World Health Organization’s Disease Outbreak News: a retrospective database
Colin J. Carlson, Matthew R. Boyce, Margaret Dunne, Ellie Graeden, Jessica Lin, Yasser Omar Abdellatif, Max A. Palys, Munir Pavez, Alexandra L. Phelan, Rebecca Katz
medRxiv 2022.03.22.22272790; doi: https://doi.org/10.1101/2022.03.22.22272790
People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses
Hope R. Lapointe, Francis Mwimanzi, Peter K. Cheung, Yurou Sang, Fatima Yaseen, Gisele Umviligihozo, Rebecca Kalikawe, Sarah Speckmaier, Nadia Moran-Garcia, Sneha Datwani, Maggie C. Duncan, Olga Agafitei, Siobhan Ennis, Landon Young, Hesham Ali, Bruce Ganase, F. Harrison Omondi, Winnie Dong, Junine Toy, Paul Sereda, Laura Burns, Cecilia T. Costiniuk, Curtis Cooper, Aslam H. Anis, Victor Leung, Daniel Holmes, Mari L. DeMarco, Janet Simons, Malcolm Hedgcock, Natalie Prystajecky, Christopher F. Lowe, Ralph Pantophlet, Marc G. Romney, Rolando Barrios, Silvia Guillemi, Chanson J. Brumme, Julio S.G. Montaner, Mark Hull, Marianne Harris, Masahiro Niikura, Mark A. Brockman, Zabrina L. Brumme
medRxiv 2022.03.22.22272793; doi: https://doi.org/10.1101/2022.03.22.22272793
“Where the truth really lies”: Listening to voices from African American communities in the Southern States about COVID-19 vaccine information and communication
Ran Zhang, Shan Qiao, Brooke McKeever, Bankole Olatosi, Xiaoming Li
medRxiv 2022.03.21.22272728; doi: https://doi.org/10.1101/2022.03.21.22272728
A Systematic Review of Human Challenge Trials, Designs, and Safety
Jupiter Adams-Phipps, Danny Toomey, Witold Więcek, Virginia Schmit, James Wilkinson, Keller Scholl, Euzebiusz Jamrozik, Joshua Osowicki, Meta Roestenberg, David Manheim
medRxiv 2022.03.20.22272658; doi: https://doi.org/10.1101/2022.03.20.22272658
Wellcome Open Research [to 26 Mar 2022]
https://wellcomeopenresearch.org/browse/articles
[Accessed 26 Mar 2022]
Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.
Study Protocol metrics AWAITING PEER REVIEW
Yoga to improve maternal mental health and immune function during the COVID-19 crisis (Yoga-M2 trial): study protocol for a pilot randomized controlled trial. [version 1; peer review: awaiting peer review]
Rahul Shidhaye, Vidyadhar Bangal, Hemant Bhargav, Swanand Tilekar, Chitra Thanage, Rakhee Suradkar, Kalpesh Game, Vandana Pulate, Sonali Tambe, Vaibhav Murhar, Rahul Kunkulol
Peer Reviewers Invited
Funders
SATYAM (Science and Technology for Yoga and Meditation) Division, Department of Science and Technology, Government of India.
The Wellcome Trust DBT India Alliance
PUBLISHED 23 Mar 2022
Systematic Review metrics
Update
A living mapping review for COVID-19 funded research projects: one year update [version 5; peer review: 2 approved]
Alice Norton, Adrian Bucher, Emilia Antonio, Nicole Advani, Cathryn Johnston, Henrike Grund, Sheila Mburu, Emma Clegg, Marguerite Gollish, Sara Sahota, Nusrat Jabin, Laura Scott, Genevieve Boily-Larouche, A. Morgan Lay, Gail Carson, Marta Tufet Bayona
Peer Reviewers David Vaughn; Peter Smith
Funders
Wellcome Trust
European Commission
UK Research and Innovation
Department of Health, Social Services and Public Safety, UK Government
LATEST VERSION PUBLISHED 22 Mar 2022
Research Article metrics
Promotion of data sharing needs more than an emergency: An analysis of trends across clinical trials registered on the International Clinical Trials Registry Platform [version 1; peer review: 1 approved]
Laura Merson, Duduzile Ndwandwe, Thobile Malinga, Giuseppe Paparella, Kwame Oneil, Ghassan Karam, Robert F. Terry
Peer Reviewer Sharon Kaur Gurmukh Singh
Funders
Wellcome Trust
Special Programme for Research and Training in Tropical Diseases (TDR) and the World Heath Organisation
PUBLISHED 21 Mar 2022
Think Tanks
Brookings
http://www.brookings.edu/
Accessed 26 Mar 2022
Coronavirus (COVID-19) Economics
Understanding the economic impact of COVID-19 on women
Claudia Goldin
Wednesday, March 23, 2022
Center for Global Development [to 26 Mar 2022]
https://www.cgdev.org/
Publications, Events [Selected]
Reexamining Global Health: Global Commons, Financing Priorities, and the Role of Institutions in the Global South
Event
3/28/22
The COVID-19 pandemic has showcased the large vulnerabilities of the global health architecture and weaknesses in the resilience of national health systems. It has also reinvigorated a debate about the right way to prioritize and use development assistance for health (DAH).
Chatham House [to 26 Mar 2022]
https://www.chathamhouse.org/
Accessed 26 Mar 2022
[No new digest content identified]
CSIS
https://www.csis.org/
Accessed 26 Mar 2022
[No new digest content identified]
Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 26 Mar 2022
March 25, 2022 News Release
New KFF Analysis Finds That the U.S. Government Does Not Currently Have Enough Vaccine Doses to Fully Cover Every American with a 4th Dose
With funding for additional COVID-19 support at a stalemate in Congress, a new KFF analysis looks at potential scenarios that United States might face if a 4th COVID-19 vaccine dose is recommended to the public. The analysis finds that the U.S. government does not have enough funding to purchase vaccine…
Rand [to 26 Mar 2022]
https://www.rand.org/pubs.html
Reports, Selected Journal Articles
Report
Pulse-Check: Exploration of Early COVID-19 Pandemic Health Care and Public Health Responses in Select Middle East Nations
This report outlines the results of an exploratory analysis of strategies used by health care systems and public health in response to COVID-19 in five countries — Iran, Jordan, Lebanon, Qatar, and Tunisia.
Mar 24, 2022
Hamad Al-Ibrahim, Nasma Berri, Emily Hoch, Nazia Wolters, Kristin J. Leuschner, Mahshid Abir
Report
Advancing Global Citizenship in America
This Perspective addresses what global citizenship is, why it is important, how it can be fostered, and ways to promote global citizenship across the political spectrum.
Mar 24, 2022
James Dobbins, Krishna B. Kumar, Karishma V. Patel
Report
The Building Resilient Infrastructure and Communities Mitigation Grant Program: Incorporating Hazard Risk and Social Equity into Decision-making Processes
The federal Building Resilient Infrastructure and Communities (BRIC) program can help develop community resilience through mitigation activities that emphasize equity goals alongside reduction of risk to physical assets, as described in this report.
Mar 23, 2022
Noreen Clancy, Melissa L. Finucane, Jordan R. Fischbach, David G. Groves, Debra Knopman, Karishma V. Patel, Lloyd Dixon
Report
Disruption Without Change: The Consequences of COVID-19 on the Global Economic Balance
The author reviews the economic track record of the United States, its competitors, and its allies to discern how economic changes induced by the COVID-19 pandemic could affect geopolitical competition and the security environment.
Mar 21, 2022
Howard J. Shatz
Vaccines and Global Health: The Week in Review is a weekly digest summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date
.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.
– pdf version: A pdf of the current issue is available here:
– blog edition: comprised of the approx. 35+ entries posted below.
– Twitter: Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links: We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.
Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.
.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy
Ukraine
WHO – Emergency in Ukraine: external situation report #3, published 17 March 2022: reporting period: 11–16 March 2022
The overall situation continues to deteriorate across Ukraine. To date, over 18 million people have been affected by the conflict. According to the latest government data compiled by the United Nations High Commissioner for Refugees (UNHCR), over three million refugees have now left Ukraine for surrounding countries, with over 60% of them in Poland. It is estimated that this number could rise to four million by July 2022.
[Excerpt]
2.2.2 Priority public health concerns
iv. Risk of emergence and spread of infectious diseases
Ongoing epidemics
A total of 35 396 new cases of COVID-19 and 556 new deaths were reported in Ukraine from 10 to 16 March. However, the seven-day average number of polymerase chain reaction tests decreased from 42 460 to 3913 from 23 February to 14 March, and the seven-day average number of antigen rapid diagnostic tests dropped from 51 484 to 3038. Therefore, the number of COVID-19 cases is likely to be underreported.
Epidemic risk
Poor ventilation and overcrowding increase the risk of spread of respiratory infections, including COVID-19. Lack of access to safe water and sanitation heightens the risk of the emergence of water-borne diseases. Of note, an outbreak of cholera was identified in Ukraine in 2011 in the Mariupol region, an area currently experiencing an escalation in conflict. A single case of cholera was also detected in the Zaporizhzhia oblast in 2016, highlighting the possibility of cholera cases occurring in parts of the country.
Suboptimal vaccination coverage of routine and childhood immunizations, including measles and poliomyelitis (polio), increases the risk of re-emergence and transmission of vaccine-preventable diseases.
With the arrival of spring and rising temperatures, disrupted access to safe water, sanitation and hygiene, and damage to homes may increase the risk of vector-borne diseases such as West Nile fever and tick-borne encephalitis.
Lack of access to barrier contraception and..increased risk of sexual and gender-based violence increases the risk of sexually transmitted infections …
Polio Vaccination – Africa
More than 80 million doses to be administered to southern African children targeted in mass polio vaccination drives
18 March 2022
Brazzaville/Lilongwe – Malawi will on Sunday launch the first round of vaccination campaigns against wild poliovirus type 1. More than 80 million doses will be administered to more than 23 million children under 5 years in the four-round vaccination drive in five southern African countries after Malawi declared an outbreak on 17 February—the first such case in the country in 30 years, and the first in Africa since the region was certified free of indigenous wild poliovirus in 2020.
The first phase of the campaigns targets 9.4 million children in Malawi, Mozambique, Tanzania and Zambia. Three subsequent rounds—in which Zimbabwe will also take part—are set for April, June and July and aim to reach over 23 million children with more than 80 million doses of the bivalent Oral Polio Vaccine recommended by World Health Organization (WHO) for wild poliovirus (type 1).
Mass vaccinations, or supplementary vaccinations, aim to interrupt the circulation of poliovirus by immunizing every child under 5 years with oral polio vaccine regardless of previous immunization status. The objective is to reach children who are either not immunized, or only partially protected, and to boost immunity in those who have been immunized. Supplementary immunization is intended to complement—not replace—routine immunization…
…The African region was declared and certified as free of indigenous wild polio in August 2020 after eliminating all forms of wild poliovirus. The region’s certification as wild polio-free remains unchanged. Laboratory analysis linked the strain detected in Malawi to the one circulating in Pakistan’s Sindh Province in 2019…
…In preparation for the vaccination drives, trained surge teams of national officers have been deployed at district level to facilitate the campaign and ensure that all eligible children are vaccinated. Maintenance and repair of cold chain facilities are also ongoing…
COVID Vaccination – Africa
Africa’s COVID-19 vaccine uptake increases by 15%
17 March 2022
Brazzaville – Africa’s COVID-19 vaccine uptake rose by 15% between January and February as several countries embarked on mass vaccination drives to expand coverage and protect populations against the adverse health impacts of the virus.
Around 62 million doses were administered across the continent in February up from 54 million in January. The uptick was driven mainly by vaccination campaigns in populous countries including Democratic Republic of the Congo, Ethiopia, Kenya, and Nigeria. To boost the COVID-19 vaccine uptake in Africa, World Health Organization (WHO), UNICEF, Gavi, the Vaccine Alliance, and partners are supporting mass vaccination drives in at least 10 priority countries to reach 100 million people by the end of April 2022…
…“The vaccination drives have ignited a positive momentum against the pandemic in Africa. With every additional person vaccinated, the weaker the power of COVID-19 over our lives becomes,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “While this progress is welcome, the pace of vaccination across the continent needs to increase nine-fold if we are to reach our target of vaccinating 70% of the population by June 2022.”
To date, the continent has fully vaccinated just 15% of the adult population. Of the 714 million doses received so far, 435 million or 61% has been administered. Fifteen countries are yet to reach 10% of their population fully vaccinated. Twenty-one African countries have fully vaccinated between 10% and 19% of their populations. Five countries have fully vaccinated between 40% and 69% of their populations. Only Mauritius and Seychelles have surpassed 70% vaccination coverage…
As Africa strives to step up vaccine uptake, it is witnessing a sustained decline in COVID-19 cases. Reported cases have fallen for nine straight weeks since the peak of the fourth pandemic wave in early January. The continent reported a 10% decline in cases in the week ending on 13 March compared with the week before. Deaths declined by 37% over the same period…
TRIPS IP Waiver – WTO Action
Wall Street Journal
World
Countries Try to Win Support for Deal to Waive Patent Protections on Covid-19 Vaccines
Compromise reached by U.S., EU, South Africa and India needs approval from World Trade Organization membership
By Saeed Shah
March 17, 2022
After 18 months of fierce debate, a group of countries, including the U.S., has reached an agreement to waive patent protections on Covid-19 vaccines. Now they are racing to get other countries to support the deal at the World Trade Organization, officials involved in the discussions said.
The U.S. and the European Union have reached a compromise with South Africa and India that would allow developing countries to manufacture Covid-19 vaccines without the permission of the holder of the intellectual-property rights. It also would set a precedent for future pandemics…
…The U.K. and Switzerland, which have major pharmaceutical industries and opposed the waiver, weren’t part of the talks on the agreement. They complained of a lack of transparency around negotiations over the deal in a WTO meeting of all members on March 9, trade officials said…
…“The difficult and protracted process has resulted in a compromise outcome,” said the U.S. Trade Representative. “While no agreement on text has been reached and we are in the process of consulting on the outcome, the U.S. will continue to engage with WTO Members as part of the Biden-Harris Administration’s comprehensive effort to get as many safe and effective vaccines to as many people as fast as possible.”…
::::::
Director-General Okonjo-Iweala hails breakthrough on TRIPS COVID-19 solution
16 March 2022
World Trade Organization Director-General Ngozi Okonjo-Iweala today warmly welcomed the breakthrough among four WTO Members on a waiver of the Trade Related Intellectual Property agreement for the production of vaccines against the COVID-19 pandemic.
“This is a major step forward and this compromise is the result of many long and difficult hours of negotiations. But we are not there yet. We have more work to do to ensure that we have the support of the entire WTO Membership,” the Director-General said.
While the agreement between the European Union, India, South Africa and the United States is an essential element to any final deal, she cautioned that not all the details of the compromise have been ironed out and that internal domestic consultations within the four members are still ongoing. Moreover, she stressed that work must commence immediately to broaden the discussions to include all 164 members of the WTO.
“In the WTO we decide by consensus, and this has not yet been achieved. My team and I have been working hard for the past three months and we are ready to roll up our sleeves again to work together with the TRIPS Council Chair Ambassador Lansana Gberie (Sierra Leone) to bring about a full agreement as quickly as possible. We are grateful to the four Members for the difficult work they have undertaken so far,” said Dr. Okonjo-Iweala.
::::::
IFPMA statement on TRIPS discussion document
16 March 2022 [Text bolding from original]
Following reports on the status of informal discussions led by the WTO Secretariat with the European Union (EU), India, South Africa, and the USA, on 16 March 2022, biopharmaceutical companies reaffirm their position that weakening patents now when it is widely acknowledged that there are no longer supply constraints of COVID-19 vaccines, sends the wrong signal.
2022 kicked off with COVID-19 vaccine production from both developing and developed country manufacturers reaching 12 billion within a year of the first vaccine being authorized. Today industry is able to produce over a billion vaccine each month. COVAX is now fully meeting its commitments. Since the beginning of 2022, there has been broad consensus that the challenge now is how to get the vaccines into the arms of people who need them, rather than vaccine supply. When the IP TRIPS Waiver was first proposed in 2020, it was to the wrong solution to the problem of scaling up manufacturing of potential COVID-19 vaccines which at the time had not yet even been authorized. Now the problem of supply has been addressed thanks to unprecedented collaboration involving companies from industrialized and developing countries, the TRIPS Waiver is not only the wrong solution, it is also an outdated proposal, that has been overtaken by events.
Weakening intellectual property (IP) will do nothing to help the scaling up of vaccine manufacturing. There is a broad consensus among experts that waiving patents would not add a single additional vaccine dose, because technology transfer goes far beyond the patent, is built on trust, know-how sharing and voluntary licensing. This is exactly what manufacturers have done on an unprecedented scale. As of now, there are 371 collaborations on vaccines manufacturing and 155 for therapeutics and, in addition, the multiple announcements of partnerships to improve geographical diversity of vaccine production, are proof in themselves that the proposed IP TRIPS waiver is unnecessary and irrelevant, at worst sends the wrong signal at the wrong time.
The IP TRIPS Waiver proposals should be recognized for what they are – political posturing that are at best a distraction, at worse creating uncertainty that can undermine innovation’s ability to respond to the current and future response to pandemics. The current proposals should be shelved; and the focus should be directed, to admittedly more difficult actions that will change lives for the better: supporting country readiness, contributing to equitable distribution, and driving innovation (Ref Three priorities to urgently increase access to COVID-19 vaccines).
::::::
OXFAM – Media reaction in response to reports of a compromise on the vaccines TRIPS waiver
16 March 2022 OXFAM
In response to reports of a potential compromise agreed by the EU, South Africa, India and the US for a waiver of intellectual property rules for COVID vaccines, Max Lawson, Head of Inequality Policy for Oxfam and co-chair of the People’s Vaccine Alliance, said:
“After almost 18 months of stalling and millions of deaths, the EU has climbed down and finally admitted that intellectual property rules and pharmaceutical monopolies are a barrier to vaccinating the world. This is a tribute to millions of campaigners across the world who have demanded a Peoples Vaccine, but this leaked proposal is not the comprehensive TRIPS waiver demanded by over 100 governments. Unless it is significantly improved it will not do enough to bring an end to vaccine apartheid and ensure access for all.
“As it stands, this proposal seems to do little to address patents beyond the existing flexibilities in the TRIPS agreement. It ignores other intellectual property barriers like trade secrets which stand in the way of vaccine manufacturers. And by focusing only on vaccines and kicking the issue of COVID-19 treatments into the long grass, it will leave life-saving treatments out of reach for millions.
“In a crisis, half measures are not acceptable. Every barrier to accessing these crucial vaccines and treatments must be cleared away. We urge member states to return to the negotiating table and come back with a comprehensive waiver that will work to cut short this pandemic and guarantee everyone is protected.”
Notes to editors
The People’s Vaccine Alliance is a coalition of nearly 100 organizations and networks, supported by Nobel Laureates, health experts, economists, Heads of States, faith leaders and activists, working together for a People’s Vaccine, available free of charge to everyone, everywhere.
::::::
Coronavirus [COVID-19] – WHO
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/diseases/novel-coronavirus-2019
Weekly Epidemiological and Operational updates
Last update: 18 Mar 2022
Confirmed cases :: 464 809 377
Confirmed deaths :: 6 062 536
Vaccine doses administered: 10 925 055 390
::::::
17 March 2022
Speech
WHO Director-General’s opening remarks at the Member State Information Session on COVID-19 – 17 March 2022
16 March 2022
Speech
WHO Director-General’s opening remarks at the WHO press conference – 16 March 2022
::::::
Weekly epidemiological update on COVID-19 – 15 March 2022
Overview
After a consistent decrease in the number of new COVID-19 cases reported globally on a weekly basis since the end of January 2022, during the week of 7 through 13 March 2022, the number of new weekly cases has increased by 8% as compared to the previous week. Across the six WHO regions, over 11 million new cases and just over 43 000 new deaths were reported. As of 13 March 2022, over 455 million confirmed cases and over 6 million deaths have been reported globally.
At the regional level, the Western Pacific Region, the African Region and the European Region reported an increase in new weekly cases of 29%, 12% and 2%, respectively, as compared with the previous week; while a decrease has been reported by the Eastern Mediterranean Region (-24%), the South-East Asia Region (-21%) and the Region of the Americas (-20%).
The number of new weekly deaths decreased globally by 17%. At the regional level, the Western Pacific Region reported an increase in new weekly deaths (+12%), while decreases were reported by the Eastern Mediterranean Region (-49%), the African Region (-41%), Europe Region (-23%), the Region of the Americas and South-East Asia Region (both -15%).
In this edition we provide:
Updates on the new WHO Designation of SARS-CoV-2 Variants
Updates on the geographic distribution of circulating SARS-CoV-2 variants of concern (VOCs), including the spread and prevalence of the Omicron variant.
Special Focus: Contact tracing and quarantine in the context of the Omicron SARS-CoV-2 variant: interim guidance
Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 02 March 2022
[Full scale view available at title link above]
[Updated on 02 March 2022]
COVID Vaccines/Therapeutics – Developer/Manufacturer Announcements
[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]
AstraZeneca
Press Releases – No new digest announcements identified
Bharat Biotech
Press Releases
Mar 16: Bharat Biotech and Biofabri partner to develop, manufacture and distribute a novel TB vaccine, MTBVAC
BioCubaFarma – Cuba
Últimas Noticias – Website not leading at inquiry
Biontech
Press Releases
Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults
15 March 2022
CanSinoBIO
News – [Website not responding at inquiry]
Clover Biopharmaceuticals – China
News
Mar 17,2022
Clover’s COVID-19 Vaccine Candidate Demonstrates Durable High Protection and Immune Responses Against Omicron as a Booster
–100% efficacy maintained against severe COVID-19 and 95% efficacy against hospitalization at five months after second dose of SCB-2019 (CpG 1018/Alum)–
–Significant neutralizing antibodies against Omicron induced by SCB-2019 (CpG 1018/Alum) third dose in both homologous and heterologous booster settings–
Curevac [Bayer Ag – Germany]
News – No new digest announcements identified
Gamaleya National Center
Latest News and Events – See Russia below.
IMBCAMS, China
Home – Website not responding at inquiry
Janssen/JNJ
Press Releases – No new digest announcements identified
Moderna
Press Releases
March 17, 2022
Moderna Submits Amendment to the Emergency Use Authorization for an Additional Booster Dose of its COVID-19 Vaccine in the U.S.
March 17, 2022
Health Canada Authorizes Moderna’s COVID-19 Vaccine in Children (6-11 Years)
Novavax
Press Releases – No new digest announcements identified
Pfizer
Recent Press Releases
03.15.2022
Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults
Sanofi Pasteur
Press Releases – No new digest announcements identified
Serum Institute of India
NEWS & ANNOUNCEMENTS – No new digest announcements identified
Shifa Pharmed [Iran]
http://shafapharmed.com/
No news page identified.
Sinopharm/WIBPBIBP
News – No new digest announcements identified
Sinovac
Press Releases
Chile Research: CoronaVac® is safe and likely to confer protection against infection caused by SARS-CoV-2 variants in participants aged 3-17 years old
2022/03/16
Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified
Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]
::::::
GSK
Press releases for media – No new digest announcements identified
Merck
News releases – No new digest announcements identified
Novartis
News – No new digest announcements identified
SK Biosciences
Press releases – No new digest announcements identified
Valneva
Press Releases – No new digest announcements identified
UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 19 Mar 2022
An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 10/22/2021 reported]
COVID-19 Global Targets and Progress Tracker – IMF
The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges. The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.
Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.
Dashboard on Vaccine Equity [accessed 19 Mar 2022]: https://data.undp.org/vaccine-equity/
See also visualization on Vaccine Access and Vaccine Affordability
Global COVID-19 Access Tracker
https://www.covid19globaltracker.org/
Duke – Launch and Scale Speedometer
The Race for Global COVID-19 Vaccine Equity
A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution
[accessed 24 July 2021]
See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research
COVID Vaccines – OCHA:: HDX
COVID-19 Data Explorer: Global Humanitarian Operations
COVID-19 Vaccine Roll-out
19 Mar 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA
Global COVID-19 Figures: 465M total confirmed cases; 6.1M total confirmed deaths
Global vaccines administered: 11.0B
Number of Countries: 28
COVAX Allocations Round 4-9 (Number of Doses): 170M
COVAX Delivered (Number of Doses): 260M
Other Delivered (Number of Doses): 260M
Total Delivered (Number of Doses): 520M
Total Administered (Number of Doses): 350M
Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]
https://data.covid19taskforce.com/data
A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.
The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.
Website accessed 19 Mar 2022: https://data.covid19taskforce.com/data The global view below is complemented by country-specific dashboards here.
vaccines and global health :: ethics and policy 